美国BioMimetic
美国仿生治疗公司（BioMimetic Therapeutics Inc.)促进肌肉骨骼损伤和疾病，包括整形外科，脊柱及运动损伤的应用愈合。仿生开发的所有产品都是基于重组人血小板衍生生长因子（rhPDGF- BB）的平台技术，这是一种生长因子，人体的主要推动者和直接刺激愈合和再生一合成形式。

Located in Franklin, Tennessee, BioMimetic is a biotechnology company specializing in the development and commercialization of innovative drug-device combination products to promote the healing of musculoskeletal injuries and diseases, including orthopedic, spine and sports injury applications. All products developed by BioMimetic are based upon recombinant human platelet-derived growth factor (rhPDGF-BB) platform technology, which is a synthetic form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration. Through the commercialization of this patented technology, BioMimetic seeks to become the leading company in the field of regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments, thus helping patients recover faster from their orthopedic injuries.

While on staff at Harvard beginning in the mid 1980s, Dr. Samuel Lynch, BioMimetic's president, CEO and founder, conducted research on the role of PDGF in tissue repair and regeneration. These efforts generated a foundation of scientific knowledge and intellectual property from which BioMimetic Therapeutics is now based.